$2.17 Billion is the total value of Rock Springs Capital Management LP's 147 reported holdings in Q3 2017. The portfolio turnover from Q2 2017 to Q3 2017 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ALXN | ALEXION PHARMACEUTICALS INC | $64,954,000 | +15.3% | 463,000 | 0.0% | 3.00% | +5.3% | |
| CI | CIGNA CORPORATION | $50,474,000 | +11.7% | 270,000 | 0.0% | 2.33% | +2.1% | |
| ISRG | INTUITIVE SURGICAL INC | $50,202,000 | +11.8% | 48,000 | 0.0% | 2.32% | +2.2% | |
| MRK | MERCK & CO INC | $48,535,000 | -0.1% | 758,000 | 0.0% | 2.24% | -8.7% | |
| WCG | WELLCARE HEALTH PLANS INC | $33,919,000 | -4.4% | 197,500 | 0.0% | 1.56% | -12.6% | |
| PEN | PENUMBRA INC | $28,038,000 | +2.9% | 310,500 | 0.0% | 1.29% | -6.0% | |
| GILD | GILEAD SCIENCES INC | $25,392,000 | +14.5% | 313,400 | 0.0% | 1.17% | +4.6% | |
| JNJ | JOHNSON & JOHNSON | $22,752,000 | -1.7% | 175,000 | 0.0% | 1.05% | -10.2% | |
| TMO | THERMO FISHER SCIENTIFIC INC | $20,812,000 | +8.4% | 110,000 | 0.0% | 0.96% | -0.9% | |
| EW | EDWARDS LIFESCIENCES CORP | $20,769,000 | -7.6% | 190,001 | 0.0% | 0.96% | -15.6% | |
| INCY | INCYTE CORP | $20,196,000 | -7.3% | 173,000 | 0.0% | 0.93% | -15.3% | |
| PRTA | PROTHENA CORP PLC | $20,046,000 | +19.7% | 309,500 | 0.0% | 0.92% | +9.3% | |
| AFAM | ALMOST FAMILY INC | $19,439,000 | -12.9% | 362,000 | 0.0% | 0.90% | -20.4% | |
| DHR | DANAHER CORP DEL | $19,301,000 | +1.6% | 225,000 | 0.0% | 0.89% | -7.2% | |
| CLVS | CLOVIS ONCOLOGY INC | $19,076,000 | -12.0% | 231,500 | 0.0% | 0.88% | -19.6% | |
| BCR | BARD C R INC | $18,429,000 | +1.4% | 57,500 | 0.0% | 0.85% | -7.4% | |
| JAZZ | JAZZ PHARMACEUTICALS PLC | $18,091,000 | -5.9% | 123,700 | 0.0% | 0.84% | -14.0% | |
| WMGI | WRIGHT MED GROUP N V | $17,333,000 | -5.9% | 670,000 | 0.0% | 0.80% | -14.0% | |
| AVXS | AVEXIS INC | $16,928,000 | +17.7% | 175,000 | 0.0% | 0.78% | +7.6% | |
| BIIB | BIOGEN INC | $16,595,000 | +15.4% | 53,000 | 0.0% | 0.77% | +5.5% | |
| BAX | BAXTER INTL INC | $14,433,000 | +3.7% | 230,000 | 0.0% | 0.67% | -5.3% | |
| ASMB | ASSEMBLY BIOSCIENCES INC | $13,619,000 | +69.1% | 390,000 | 0.0% | 0.63% | +54.3% | |
| ALNY | ALNYLAM PHARMACEUTICALS INC | $12,336,000 | +47.3% | 105,000 | 0.0% | 0.57% | +34.5% | |
| HLS | HEALTHSOUTH CORP | $12,283,000 | -4.2% | 265,000 | 0.0% | 0.57% | -12.5% | |
| BMRN | BIOMARIN PHARMACEUTICAL INC | $11,634,000 | +2.5% | 125,000 | 0.0% | 0.54% | -6.3% | |
| ACRS | ACLARIS THERAPEUTICS INC | $11,356,000 | -4.8% | 440,000 | 0.0% | 0.52% | -13.1% | |
| ARDX | ARDELYX INC | $11,200,000 | +9.8% | 2,000,000 | 0.0% | 0.52% | +0.4% | |
| XENT | INTERSECT ENT INC | $10,747,000 | +11.4% | 345,000 | 0.0% | 0.50% | +1.8% | |
| JUNO | JUNO THERAPEUTICS INC | $10,094,000 | +50.1% | 225,000 | 0.0% | 0.47% | +37.1% | |
| RTRX | RETROPHIN INC | $9,956,000 | +28.4% | 400,000 | 0.0% | 0.46% | +17.1% | |
| CO | CHINA CORD BLOOD CORP | $9,786,000 | +17.3% | 880,000 | 0.0% | 0.45% | +7.1% | |
| NEURODERM LTD | $9,247,000 | +30.1% | 237,700 | 0.0% | 0.43% | +18.9% | ||
| RTIX | RTI SURGICAL INC | $8,873,000 | -22.2% | 1,950,000 | 0.0% | 0.41% | -29.0% | |
| RARX | RA PHARMACEUTICALS INC | $8,760,000 | -22.1% | 600,000 | 0.0% | 0.40% | -28.9% | |
| TXMD | THERAPEUTICSMD INC | $8,464,000 | +0.4% | 1,600,000 | 0.0% | 0.39% | -8.5% | |
| CLSD | CLEARSIDE BIOMEDICAL INC | $8,172,000 | -4.1% | 935,000 | 0.0% | 0.38% | -12.3% | |
| AIMT | AIMMUNE THERAPEUTICS INC | $7,263,000 | +20.6% | 293,000 | 0.0% | 0.34% | +10.2% | |
| ADAP | ADAPTIMMUNE THERAPEUTICS PLCsponds adr | $7,166,000 | +82.4% | 875,000 | 0.0% | 0.33% | +67.2% | |
| REGN | REGENERON PHARMACEUTICALS | $7,154,000 | -9.0% | 16,000 | 0.0% | 0.33% | -16.9% | |
| OBSV | OBSEVA SA | $6,838,000 | -4.8% | 840,000 | 0.0% | 0.32% | -13.2% | |
| CRVS | CORVUS PHARMACEUTICALS INC | $6,736,000 | +31.7% | 422,600 | 0.0% | 0.31% | +20.5% | |
| MEDICINES COnote 2.750% 7/1 | $5,281,000 | +0.5% | 5,000,000 | 0.0% | 0.24% | -7.9% | ||
| GBT | GLOBAL BLOOD THERAPEUTICS IN | $4,658,000 | +13.5% | 150,000 | 0.0% | 0.22% | +3.9% | |
| ADRO | ADURO BIOTECH INC | $4,420,000 | -6.6% | 415,000 | 0.0% | 0.20% | -14.6% | |
| EXEL | EXELIXIS INC | $4,240,000 | -1.6% | 175,000 | 0.0% | 0.20% | -10.1% | |
| MGNX | MACROGENICS INC | $4,158,000 | +5.5% | 225,000 | 0.0% | 0.19% | -3.5% | |
| EGALET CORPnote 5.500% 4/0 | $4,051,000 | -19.0% | 7,800,000 | 0.0% | 0.19% | -26.1% | ||
| MEDICINES COnote 2.500% 1/1 | $3,801,000 | -2.9% | 3,000,000 | 0.0% | 0.18% | -11.6% | ||
| AGNPRA | ALLERGAN PLCpfd conv ser a | $3,789,000 | -12.6% | 5,000 | 0.0% | 0.18% | -20.1% | |
| DVAX | DYNAVAX TECHNOLOGIES CORP | $3,548,000 | +122.9% | 165,000 | 0.0% | 0.16% | +105.0% | |
| MCRB | SERES THERAPEUTICS INC | $3,529,000 | +42.0% | 220,000 | 0.0% | 0.16% | +29.4% | |
| BMY | BRISTOL MYERS SQUIBB CO | $3,187,000 | +14.4% | 50,000 | 0.0% | 0.15% | +4.3% | |
| CGEN | COMPUGEN LTDord | $3,135,000 | 0.0% | 825,000 | 0.0% | 0.14% | -8.2% | |
| DBVT | DBV TECHNOLOGIES S Asponsored adr | $3,098,000 | +18.8% | 73,000 | 0.0% | 0.14% | +8.3% | |
| ITCI | INTRA CELLULAR THERAPIES INC | $2,959,000 | +27.1% | 187,500 | 0.0% | 0.14% | +16.1% | |
| AGLE | AEGLEA BIOTHERAPEUTICS INC | $2,584,000 | +28.4% | 524,089 | 0.0% | 0.12% | +16.7% | |
| CRME | CARDIOME PHARMA CORP | $2,568,000 | -52.7% | 1,200,000 | 0.0% | 0.12% | -56.9% | |
| RIGL | RIGEL PHARMACEUTICALS INC | $2,540,000 | -7.0% | 1,000,000 | 0.0% | 0.12% | -15.2% | |
| ZBH | ZIMMER BIOMET HLDGS INC | $2,471,000 | -8.8% | 21,100 | 0.0% | 0.11% | -16.8% | |
| CDTX | CIDARA THERAPEUTICS INC | $2,430,000 | +8.0% | 300,000 | 0.0% | 0.11% | -1.8% | |
| LIFE | ATYR PHARMA INC | $2,399,000 | +48.5% | 475,000 | 0.0% | 0.11% | +35.4% | |
| THERAVANCE BIOPHARMA INCnote 3.250%11/0 | $1,844,000 | -9.3% | 1,500,000 | 0.0% | 0.08% | -17.5% | ||
| SCYX | SCYNEXIS INC | $1,832,000 | +34.7% | 760,000 | 0.0% | 0.08% | +23.2% | |
| CHMA | CHIASMA INC | $1,256,000 | +75.9% | 492,500 | 0.0% | 0.06% | +61.1% | |
| WRIGHT MED GROUP INCnote 2.000% 2/1 | $1,086,000 | -2.7% | 1,000,000 | 0.0% | 0.05% | -10.7% | ||
| PTI | PROTEOSTASIS THERAPEUTICS IN | $945,000 | -55.1% | 450,000 | 0.0% | 0.04% | -58.5% | |
| NVAX | NOVAVAX INC | $935,000 | -0.8% | 820,000 | 0.0% | 0.04% | -10.4% | |
| NLNK | NEWLINK GENETICS CORP | $738,000 | +38.5% | 72,500 | 0.0% | 0.03% | +25.9% | |
| TNDM | TANDEM DIABETES CARE INC | $411,000 | -8.7% | 562,500 | 0.0% | 0.02% | -17.4% | |
| EGLTQ | EGALET CORP | $384,000 | -46.0% | 300,000 | 0.0% | 0.02% | -50.0% | |
| INFI | INFINITY PHARMACEUTICALS INC | $359,000 | -15.3% | 270,000 | 0.0% | 0.02% | -19.0% | |
| OREXQ | OREXIGEN THERAPEUTICS INC | $350,000 | -26.9% | 165,300 | 0.0% | 0.02% | -33.3% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| INTUITIVE SURGICAL INC | 40 | Q3 2023 | 3.4% |
| NEUROCRINE BIOSCIENCES INC | 39 | Q3 2023 | 4.8% |
| PACIRA PHARMACEUTICALS INC | 39 | Q3 2023 | 2.6% |
| ULTRAGENYX PHARMACEUTICAL IN | 39 | Q3 2023 | 1.9% |
| ACADIA HEALTHCARE COMPANY IN | 38 | Q3 2023 | 4.4% |
| ASCENDIS PHARMA A/S | 35 | Q3 2023 | 1.3% |
| INVITAE CORP | 35 | Q3 2023 | 1.8% |
| BIOMARIN PHARMACEUTICAL INC | 35 | Q3 2023 | 1.3% |
| MACROGENICS INC | 35 | Q3 2023 | 0.5% |
| COLLEGIUM PHARMACEUTICAL INC | 34 | Q3 2023 | 2.1% |
View Rock Springs Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 3,413,906 | 5.6% |
| Compass Therapeutics, Inc. | February 14, 2023 | 5,333,188 | 4.2% |
| Mirum Pharmaceuticals, Inc. | February 14, 2023 | 1,795,733 | 4.9% |
| PhaseBio Pharmaceuticals IncSold out | February 14, 2023 | 0 | 0.0% |
| Sierra Oncology, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ARDELYX, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| CHIASMA, INCSold out | February 15, 2022 | 0 | 0.0% |
| FIVE PRIME THERAPEUTICS, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| F-star Therapeutics, Inc. | February 15, 2022 | 751,889 | 3.6% |
| Protara Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
View Rock Springs Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-01 |
| SC 13G/A | 2024-04-05 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Rock Springs Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.